Literature DB >> 2835441

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.

D Bajorin1, A Katz, E Chan, N Geller, N Vogelzang, G J Bosl.   

Abstract

To evaluate the potential effect of patient selection on chemotherapy trials for patients with advanced germ cell tumors (GCT), four sets of eligibility criteria for poor risk trials were compared in 118 patients. A significant difference was found in the number of patients designated poor risk by the various criteria (P less than .005). Disagreement in the risk assignment by the various selection criteria was seen in 44% of patients. Initial complete response (CR) rates in patients designated poor risk by the various criteria ranged from 38% to 62%. Initial CR rates as high as 94% were seen in patients considered to be poor risk by one set of criteria, but good risk by another. Substantial differences in sensitivity, specificity, overall predictive value, and survival distributions were observed for the various selection criteria. Randomized trials will be necessary to reduce the influence of eligibility criteria on trial outcome and conclusions.

Entities:  

Mesh:

Year:  1988        PMID: 2835441     DOI: 10.1200/JCO.1988.6.5.786

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

Review 1.  Treatment intensification in disseminated germ-cell tumors.

Authors:  J Beyer; C Bokemeyer; H J Schmoll; W Siegert
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

2.  Malignant germ cell tumor of the mediastinum: a multimodality therapeutic approach.

Authors:  H Asamura; R Tsuchiya; T Goya; H Kondo; T Naruke; N Saijo; K Suemasu
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

3.  Simulation studies and the alignment of interests.

Authors:  Godefridus G van Merode; Siebren Groothuis; Milou Schoenmakers; Hendrikus H Boersma
Journal:  Health Care Manag Sci       Date:  2002-04

Review 4.  Optimal drug therapy in the treatment of testicular cancer.

Authors:  E R Priest; N J Vogelzang
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

5.  Application of the International Germ Cell Consensus Classification to the Nova Scotia population of patients with germ cell tumours.

Authors:  Elana Maydanski Murphy; Jo-Anne Douglas; Kara Thompson; Lori Wood
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

Review 6.  High-dose therapy with stem cell support in solid tumors.

Authors:  G Spitzer; F R Dunphy; C E Bowers; D R Adkins
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

7.  Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.

Authors:  R N Hitchins; E S Newlands; D B Smith; R H Begent; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

Review 8.  Germ cell tumour chemotherapy.

Authors:  A Horwich
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

9.  Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.

Authors:  R de Wit; R Sylvester; C Tsitsa; P H de Mulder; D T Sleyfer; W W ten Bokkel Huinink; S B Kaye; A T van Oosterom; E Boven; K Vermeylen; G Stoter
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Bone disease in testicular and extragonadal germ cell tumours.

Authors:  R N Hitchins; P A Philip; B Wignall; E S Newlands; R H Begent; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.